Harvard Medical School and Cellectricon collaborates Around Whole-Genome RNAi Screening Technology
News Nov 26, 2008
Cellectricon has announced its collaboration with Harvard Medical School, the ICCB-Longwood Screening Facility. Harvard Medical School (ICCB-L) will utilize the Cellaxess®HT system, a system for high throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types.
“We are excited about the collaboration with Cellectricon and the opportunity we have to evaluate Cellaxess®HT for genome-wide RNAi delivery to biologically relevant cell types”, says Caroline Shamu, Director of ICCB-L.
“Cellectricon is extremely proud to collaborate with a world-class research institution such as Harvard Medical School (ICCB-L)”, says Jonas Ohlsson, CEO at Cellectricon. We look forward to jointly advance the RNAi research area by our technology, as we’re confident that Cellaxess®HT will aid in the generation of more relevant results from RNAi screening campaigns.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.